Group 1: Stock Performance - Yiming Pharmaceutical achieved a 10.00% increase over two consecutive days, driven by developments in Tibet and medical technology [3] - Kantai Medical saw a first board listing with a 20.03% rise, attributed to medical device advancements [4] - Zhengchuan Co. also debuted on the first board with a 9.99% increase, linked to medicinal glass [3] - Yuheng Pharmaceutical and Tianmu Pharmaceutical both recorded first board listings with increases of 10.09% and 10.00% respectively, related to the pharmaceutical sector [3] Group 2: AI and Robotics - Zhi Zhen Technology and Zhongdian Xinlong both debuted on the first board with a 10.01% increase, associated with computing power and machine learning [6] - Hubei Broadcasting and Duolun Technology also saw first board listings with increases of 10.04% and 9.95%, driven by computing power and AI applications [7] - The M-Robots open-source project was announced, aiming to create a unified robot operating system [11] Group 3: Infrastructure and Energy - The announcement of a 1.2 trillion yuan investment in a super hydropower project has led to significant interest in related stocks [13][16] - Nanfang Road Machinery and Tuoshan Heavy Industry both achieved consecutive board listings with increases of 9.99% and 10.01%, linked to engineering machinery [15] Group 4: Tourism and Hospitality - The demand for various types of tourism, including educational and family trips, has surged, with national railways reporting 341 million passenger trips [18][19] - Sizhizang Tourism and Tianfu Cultural Tourism both recorded first board listings with increases of 9.99% and 10.04%, reflecting the growing tourism sector [20] Group 5: Market Trends - The stock market has shown a strong focus on sectors such as robotics, AI, and infrastructure, with multiple companies achieving significant stock price increases [22][23]

Group 1 - The A-share ophthalmology sector experienced a volatile rebound, with Tianmu Pharmaceutical hitting the daily limit up [1] - Other companies such as Xingqi Eye Medicine, Laimei Pharmaceutical, Nuo Silan De, and Daheng Technology also saw increases in their stock prices [1]

Group 1 - The company has increased its subsidiary Huangshan Tianmu Pharmaceutical's registered capital from 30 million to 80 million yuan, with an investment of 50 million yuan from its own funds [1] - The business scope of Huangshan Tianmu includes drug production and import/export, medical device sales, health food, and cosmetics, covering traditional Chinese medicine and health consumer products [1] - The company plans to invest approximately 100 million yuan to build new production facilities and optimize existing production lines, enhancing overall capacity and efficiency [1] Group 2 - Huangshan Tianmu has made progress in drug re-registration, obtaining approval for several products since May, including Compound Danshen Tablets and other traditional Chinese medicines [2] - The company is focusing on a dual strategy of "premium traditional Chinese medicine + health" to strengthen its market position in the health sector [2] - The company aims to innovate products and expand sales channels, including online and offline strategies, to meet consumer demand for health products [2] Group 3 - The company is collaborating with its subsidiaries and medical teams to enhance product development and market expansion in health products [3] - New product forms such as lozenges and soft capsules are being introduced to diversify the product portfolio and create new profit growth points [3] - The company emphasizes the importance of product quality control, brand building, and marketing strategies to meet the growing consumer demand for high-quality health products [3]

关于向子公司增资事项完成工商变更登记的公告 证券代码：600671 证券简称：天目药业 公告编号：临 2025-033 杭州天目山药业股份有限公司 重要内容提示： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 ? 本次仅涉及黄山市天目药业有限公司（以下简称"黄山天目"）注册资 本和企业类型变更。 类型：有限责任公司（非自然人投资或控股的法人独资） 法定代表人：李峰 注册资本：捌仟万圆整 成立日期：1997-10-28 杭州天目山药业股份有限公司（以下简称"公司"）于 2025 年 3 月 11 日在 上海证券交易所网站（www.sse.com.cn）披露的《关于向全资子公司黄山市天目 药业有限公司增资的公告》。公司拟以自有资金向全资子公司黄山天目增资人民 币 5,000 万元，增资完成后，黄山天目的注册资本将由 3,000 万元增至 8,000 万元，黄山天目仍为公司全资子公司。上述事项已经公司 2025 年第一次临时股 东大会审议通过。 近日，公司收到黄山天目通知，其完成了注册资本和企业类型工商变更登记 和章程备案登记手续 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-033 杭州天目山药业股份有限公司 关于向子公司增资事项完成工商变更登记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 类型：有限责任公司（非自然人投资或控股的法人独资） 法定代表人：李峰 注册资本：捌仟万圆整 成立日期：1997-10-28 重要内容提示： 本次仅涉及黄山市天目药业有限公司（以下简称"黄山天目"）注册资 本和企业类型变更。 杭州天目山药业股份有限公司（以下简称"公司"）于 2025 年 3 月 11 日在 上海证券交易所网站（www.sse.com.cn）披露的《关于向全资子公司黄山市天目 药业有限公司增资的公告》。公司拟以自有资金向全资子公司黄山天目增资人民 币 5,000 万元，增资完成后，黄山天目的注册资本将由 3,000 万元增至 8,000 万元，黄山天目仍为公司全资子公司。上述事项已经公司 2025 年第一次临时股 东大会审议通过。 近日，公司收到黄山天目通知，其完成了注册资本和企业类型工商变更登记 和章程备案登记手续，并 ...

杭州天目山药业股份有限公司 关于子公司收到药品再注册批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"）获悉，公司下属子公司 黄山市天目药业有限公司（以下简称"黄山天目"）和黄山天目薄荷药业有限公 司（以下简称"天目薄荷"）于近日收到安徽省药品监督管理局核准签发的《药 品再注册批准通知书》。现将相关情况公告如下： 证券代码：600671 证券简称：天目药业 公告编号：临 2025-032 | 10 | 桑菊 | 黄山 | 片剂 | 每片重 | 国药准字 | 中药 | 《中国药典》 | 2025R066163 | 至 | 2030 年 | 疏风清热，宣肺止咳。用于 风热感冒初起，头痛，咳嗽， | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 感冒片 | 天目 | | 0.6g | Z34020318 | | 2020 年版一部 | | 07 月 | 15 日 | ...

Core Viewpoint - Tianmu Pharmaceutical (600671) has received approval for multiple drug re-registrations from the Anhui Provincial Drug Administration, which is expected to positively impact the company's production, sales, and promotion efforts [1] Group 1: Drug Approvals - The approved drugs include: - Bu Shen Qiang Shen Pian (补肾强身片) - Chuan Xin Lian Jiao Nang (穿心莲胶囊) - Gan Mao Qing Pian (感冒清片) - Gan Mao Tui Re Ke Li (感冒退热颗粒) - Hou Tou Jun Pian (猴头菌片) - Jin Gu Cao Pian (筋骨草片) - Ling Qiao Jie Du Pian (羚翘解毒片) - Ling Yang Gan Mao Pian (羚羊感冒片) - Nao De Sheng Pian (脑得生片) - Sang Ju Gan Mao Pian (桑菊感冒片) - Shou Wu Yan Shou Pian (首乌延寿片) - Yang Xue An Shen Pian (养血安神片) [1] Group 2: Approval Validity and Application - The approval notification is valid until 2030 and is applicable for conditions such as lower back pain, dizziness, and tinnitus [1]

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company forecasts a return to profitability in H1 2025, with net profit attributable to parent shareholders projected from RMB 8.5 million to RMB 10.5 million 2025 Semi-Annual Performance Forecast | Indicator | Estimated Amount (RMB) | Compared to Same Period Last Year | | :--- | :--- | :--- | | Net Profit Attributable to Parent | RMB 8.5 million - RMB 10.5 million | Expected Increase of RMB 27.0007 million - RMB 29.0007 million | | Net Profit After Non-recurring Items | RMB 4.1 million - RMB 6.1 million | Not Applicable | - The company expects to **turn losses into profits** in the first half of 2025[4](index=4&type=chunk) - This performance forecast has **not been audited** by a certified public accountant[3](index=3&type=chunk) [Prior Period Operating Performance](index=2&type=section&id=II.%20Prior%20Period%20Operating%20Performance%20and%20Financial%20Position) In the prior period of 2024, the company reported a net loss attributable to parent company shareholders of RMB 18.5007 million 2024 Semi-Annual Performance Review | Indicator | Amount (RMB) | | :--- | :--- | | Net Profit Attributable to Parent | RMB -18.5007 million | | Net Profit After Non-recurring Items | RMB -22.0571 million | | Earnings Per Share | RMB -0.1519 | [Primary Reasons for Performance Pre-profit](index=2&type=section&id=III.%20Primary%20Reasons%20for%20Current%20Period%20Performance%20Pre-profit) Return to profitability is primarily driven by enhanced terminal sales across pharmaceutical, health product, and medical device segments - The primary driver of performance growth is the company's continued focus on **core strengths**, strengthening the layout and **terminal sales** of pharmaceutical, health product, and medical device segments[7](index=7&type=chunk) - These measures led to a **significant year-on-year increase** in the company's product sales volume and revenue, improving **overall profitability**[7](index=7&type=chunk) [Risk Warning and Other Explanations](index=2&type=section&id=IV.%20Risk%20Warning) This performance forecast is a preliminary, unaudited estimate, with final data subject to the official 2025 semi-annual report - This performance forecast is a **preliminary estimate** by the company's finance department based on its professional judgment and has **not yet been audited** by a certified public accountant[8](index=8&type=chunk) - The company states that there are **no significant uncertainties** affecting the accuracy of this performance forecast[8](index=8&type=chunk) - The **final accurate financial data** will be subject to the company's officially disclosed 2025 semi-annual report, and investors are advised to be aware of **investment risks**[9](index=9&type=chunk)

| | 一、药品基本情况 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序 号 | 产品 名称 | 药品生 产企业 | 剂型 | 规格 | 药品 | 注册 | 药品注册 | 通知书编号 | 药品 批准文号 | 适用症 | | | | | | | 批准文号 | 分类 | 标准编号 | | 有效期 | 活血化瘀，理气止痛。用于 | | 1 | 复方 | 黄山 | 片剂 | 每片重 | 国药准字 | 中药 | 《中国药典》 | 2025R050976 | 至 2030 年 | 气滞血瘀所致的胸痹，症见 | | | 丹参片 | 天目 | | 0.25g | Z34020312 | | 2020 版一部 | | 06 月 05 日 | 胸闷、心前区刺痛；冠心病 | | | | | | | | | | | | 心绞痛见上述证候者。 | | | | | | | | | 部颁标准中药 | | | 滋养肝肾，祛风明目。用于 | | 2 | 桑麻丸 | 黄山 | 丸剂 | 每 50 粒 重约 3g ...

Performance Meeting Overview - The company held its 2024 annual performance meeting on June 5, 2025, via an online interactive format at the Shanghai Stock Exchange [1] - Key executives including the Secretary of the Board, CFO, and an independent director participated in the meeting to address investor inquiries [1] Product Registration and Development - As of now, the company has completed re-registration for 29 drug numbers at its Lin'an Pharmaceutical Center, with 11 drug numbers at Huangshan Tianmu and Huangshan Mint also completed [2] - The company is working on small-scale trials and commissioned processing for some re-registered drug numbers to enhance its product diversity [2] Key Product Updates - The company's flagship product, Pearl Eye Drops, is undergoing preparations for GMP compliance checks, but the timeline for resuming normal production and sales remains uncertain [2] - The company has launched White Flower Snake Grass Water in collaboration with East China Grape Brewing Co., achieving sales revenue of 342.32 million yuan in 2024 [2] Health Product Strategy - The company is focused on a dual strategy of "premium traditional Chinese medicine + health products," aiming to expand its health product offerings [3] - New products such as Iron Skin Fengtou tablets, soft capsules, and extracts have been added to the existing product line [3] Collaborations and Market Expansion - The company has established a subsidiary for research and development in traditional Chinese medicine and health products, collaborating with renowned TCM teams [3] - Partnerships with Qingdao University aim to innovate TCM applications in health foods and functional products [3] E-commerce Initiatives - The company launched its flagship store on Tmall in May 2025, facilitating online sales of its Iron Skin Fengtou product line [4] - The company plans to leverage internet channels to enhance product promotion and expand market share [4] Mergers and Acquisitions - The company has adopted a cautious yet open approach to mergers and acquisitions, having acquired 51% stakes in Qingdao Simulation Medical Technology Co., Ltd. and Qingdao Tianmu Mountain Medical Technology Co., Ltd. in 2024 [5] - These acquisitions are expected to improve asset quality and enhance the company's operational capabilities [5]